



Intarcia Ref. No. INT 004.10
USSN 10/004,118
PATENT

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Gary R. Fabian

Printed Name

Signature

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stanford Mark Moran

Confirmation No. 8022

Serial No.: 10/004,118

Art Unit: 1647

Filing Date: 30 October 2001

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended --
METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON --

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copies of the cited references accompany this paper.

Further, because this application was filed after 30 June 2003, copies of the cited U.S. Patent publication has not been submitted pursuant to the waiver described in pre-OG Notice "Information Disclosure Statements may be filed without copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record in the present application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to

the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Authorization to Charge Deposit Account:

The Commissioner is hereby authorized to charge **\$180.00** under 1.17(p) for Submission of an Information Disclosure Statement to Deposit Account No. **504212** (please reference docket number **INT 004.10**). No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** (please reference docket number **INT 004.10**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Date: 29 May 2007

By: Gary R. Fabian
Gary R. Fabian, Ph.D.
Agent for Applicants
Registration No. 33,875

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dkt No. INT 004.10



FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 1

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended -- METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON --

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	DA-01	6,875,748	April 5, 2005	Manthorpe, et al.			
	DA-						

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
	DB-01	WO 00/40273A2	13 July 2000	WIPO/PCT			
	DB-02	WO 00/40273A3	13 July 2000	WIPO/PCT			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	DC-	
	DC-	

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.